European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients who developed LRTI had a 2.7-fold

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. In the U.S., SELECT Trial Results : Semaglutide 2.4

CME 103

CME Obesity Heart Failure Biomarkers 103

Cardiometabolic Health Congress

JULY 25, 2023

Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52